Watch SPRY. Know when insiders buy.
One email the day a filing lands. Free.
SPRY
ARS Pharmaceuticals, Inc.
4.07
−0.01 −0.30%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
47
WATCH · shorts 47
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $404.5MP/E —DIV YIELD —FCF YIELD -48.60%REV TTM $116.9M +4.1%NET INCOME −$215.4MNET DEBT $88.5M52W 4.07 – 13.06SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $33.7M | +114.2% | — | −$61.5M | −$62.3M | — | -0.63 | −$60.9M | $0 | −$60.9M | Aug 13 |
| Q1 2026 · Mar 31 | $22.7M | +184.5% | — | −$60.1M | −$60.6M | — | -0.61 | −$44.9M | $0 | −$44.9M | May 15 |
| Q4 2025 · Dec 31derived | $28.1M | −67.6% | — | −$41.5M | −$41.3M | −182.8% | -0.42 | −$43.5M | $0 | −$43.5M | Mar 9 |
| Q3 2025 · Sep 30 | $32.5M | +1471.6% | — | −$53.2M | −$51.2M | — | -0.52 | −$47M | $197K | −$47.2M | Nov 10 |
| Q2 2025 · Jun 30 | $15.7M | +3043.4% | — | −$47.6M | −$44.9M | — | -0.46 | −$39.6M | $51K | −$39.6M | Aug 13 |
| Q1 2025 · Mar 31 | $8M | — | — | −$37.2M | −$33.9M | — | -0.35 | −$40.7M | $91K | −$40.8M | May 15 |
| Q4 2024 · Dec 31derived | $86.6M | — | — | $47.2M | $49.9M | — | 0.51 | $42M | $302K | $41.7M | Mar 9 |
| Q3 2024 · Sep 30 | $2.1M | — | — | −$21.7M | −$19.1M | — | -0.20 | −$14.5M | $140K | −$14.6M | Nov 10 |
| Q2 2024 · Jun 30 | $500K | — | — | −$15.3M | −$12.5M | — | -0.13 | −$7.3M | $38K | −$7.3M | Aug 13 |
| Q1 2024 · Mar 31 | $0 | — | — | −$13.2M | −$10.3M | — | -0.11 | −$6.7M | $83K | −$6.8M | May 14 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$10.2M | −$7.2M | — | -0.07 | −$17.4M | −$91K | −$17.3M | Mar 20 |
| Q3 2023 · Sep 30 | $0 | — | — | −$18M | −$14.9M | — | -0.16 | −$12.8M | $43K | −$12.8M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $84.3M | — | −$179.4M | −$171.3M | -203.3% | -1.74 | −$170.9M | $339K | −$171.2M | — | — |
| FY2024 · to Dec 31 | $89.1M | — | −$3.1M | $8M | 9.0% | 0.08 | $13.5M | $563K | $13M | — | — |
| FY2023 · to Dec 31 | $30K | 100.0% | −$67.5M | −$54.4M | -181216.7% | -0.57 | −$59.3M | $175K | −$59.4M | — | — |
| FY2022 · to Dec 31 | $1.3M | — | −$35.5M | −$34.7M | -2635.4% | -0.87 | −$40.1M | $199K | −$40.3M | — | — |
| FY2021 · to Dec 31 | $5.5M | — | −$19.5M | −$20.2M | -367.7% | -0.70 | −$17.6M | $55K | −$17.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$32.9M | −$32.9M | — | -11.33 | −$31.2M | $917K | −$32.1M | — | — |
Every number comes from ARS Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.